Lp(a)
Lp(a) is a lipoprotein particle whose main constituent is apolipoprotein(a), the product of the LPA gene. Apo(a) is a kringle-containing serine proteinase that inhibits tissue-type plasminogen activator, and elevated plasma levels are linked to atherosclerosis. Browse Assay Genie's current range of Lp(a) research reagents below, or read on for the biology behind the target.
Apolipoprotein(a), or apo(a), is the main constituent of lipoprotein(a), written Lp(a). It has serine proteinase activity and is capable of autoproteolysis. Apo(a) inhibits the activity of tissue-type plasminogen activator, and Lp(a) may also act as a ligand for megalin (Gp330). The protein is proteolytically cleaved, and the resulting fragments attach to atherosclerotic lesions and promote thrombogenesis.
The LPA gene encodes apo(a), which makes up a substantial portion of the Lp(a) particle. UniProt places it in the peptidase S1 family, plasminogen subfamily, and HGNC classifies it among the serine proteases and kringle domain containing proteins. A distinctive feature of the Lp(a) protein is its variable size: depending on the individual, it contains between 2 and 43 copies of kringle-type domains. The allele represented in the reference genome sequence contains 15 copies of the kringle-type repeats. This copy-number variation is important to keep in mind when comparing Lp(a) measurements and constructs between samples or individuals.
Lp(a) is of interest in cardiovascular research because elevated plasma levels of the protein are linked to atherosclerosis. Its inhibition of tissue-type plasminogen activator and the attachment of its cleavage fragments to atherosclerotic lesions connect it to both fibrinolysis and thrombogenesis. HGNC records the previous names as lipoprotein and Lp(a), and the symbol LP has also been used for the gene.
Elevated plasma Lp(a) is linked to atherosclerosis, and apo(a) fragments attach to atherosclerotic lesions, making the protein a focus for studies of lesion biology.
Apo(a) inhibits tissue-type plasminogen activator and its fragments promote thrombogenesis, so Lp(a) is studied where coagulation and fibrinolysis intersect.
As the main constituent of the Lp(a) particle, apo(a) is central to work on how this lipoprotein is assembled and handled in plasma.
Individuals carry 2 to 43 kringle-type repeats, giving a useful model for studying how domain copy number shapes protein size and function.
Apo(a) is the main constituent of Lp(a). It has serine proteinase activity, can undergo autoproteolysis and inhibits tissue-type plasminogen activator. Cleavage fragments attach to atherosclerotic lesions and promote thrombogenesis, and Lp(a) may be a ligand for megalin (Gp330).
The HGNC gene name is lipoprotein(a), with the symbol LPA. Aliases include Lp(a) and LP, and previous names are lipoprotein and Lp(a). The encoded protein is called apolipoprotein(a), or apo(a), and forms the main part of the Lp(a) particle.
Depending on the individual, the protein contains 2 to 43 kringle-type domain copies; the reference allele has 15. Elevated plasma levels of Lp(a) are linked to atherosclerosis. Check the datasheet of any product for its validated reactivity.
Plasminogen-related proteases, fibrinolysis regulators and lipoprotein-handling proteins connected to Lp(a) biology.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P08519; product specifications from Assay Genie datasheets.